BRIEF-Johnson & Johnson Announces Submission Of Application To The U.S. FDA For Emergency Use Authorization Of Its Investigational Single-Shot Janssen Covid-19 Vaccine Candidate

Feb 4 (Reuters) - Johnson & Johnson JNJ.N:

• JOHNSON & JOHNSON ANNOUNCES SUBMISSION OF APPLICATION TO THE U.S. FDA FOR EMERGENCY USE AUTHORIZATION OF ITS INVESTIGATIONAL SINGLE-SHOT JANSSEN COVID-19 VACCINE CANDIDATE

• JOHNSON & JOHNSON ANNOUNCES SUBMISSION OF APPLICATION TO THE U.S. FDA FOR EMERGENCY USE AUTHORIZATION OF ITS INVESTIGATIONAL SINGLE-SHOT JANSSEN COVID-19 VACCINE CANDIDATE

• J&J - INTENDS TO DISTRIBUTE VACCINE TO U.S. GOVERNMENT IMMEDIATELY FOLLOWING AUTHORIZATION

• J&J - EXPECTS TO SUPPLY 100 MILLION DOSES TO U.S. IN FIRST HALF OF 2021

• J&J - EXPECTS TO HAVE PRODUCT AVAILABLE TO SHIP IMMEDIATELY FOLLOWING AUTHORIZATION

• J&J - WILL SUBMIT A CONDITIONAL MARKETING AUTHORISATION APPLICATION (CMAA) WITH EUROPEAN MEDICINES AGENCY IN COMING WEEKS

• J&J - INITIATED ROLLING SUBMISSIONS WITH SEVERAL HEALTH AGENCIES OUTSIDE U.S.

Source text for Eikon: ID:nPn7ZRgY0a

Further company coverage: JNJ.N

((Reuters.Briefs@thomsonreuters.com;))